megakaryocyte


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

megakaryocyte

[¦meg·ə′kar·ē·ə‚sīt]
(histology)
A giant bone-marrow cell characterized by a large, irregularly lobulated nucleus; precursor to blood platelets.
References in periodicals archive ?
In its previous studies, Cellerant demonstrated that megakaryocyte progenitor cells were able to produce human platelets in preclinical models with in vivo functionality similar to that of normal human platelets.
The mRNAs included control housekeeping genes [actin, beta (ACTB) [4] and beta-2-microglobulin (B2M)] and myeloid [defensin, alpha 3, neutrophil-specific (DEFA3) and serglycin (SRGN)], erythroid [hemoglobin, beta (HBB) and uroporphyrinogen decarboxylase (UROD)], and megakaryocyte [integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) (ITGA2B) and integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) (ITGB3)] lineage-specific genes.
12) showed significant suppression of megakaryocyte colony formation of normal marrow cells with the addition of AATP patient serum to marrow cultures.
The time course of DIT related to marrow suppression is generally slow, often for several weeks, reflecting the time required to deplete the megakaryocyte population (Figure 1).
Prominent multilineage dysplasia is common, but variable, involving granulocytes (Figure 2, C) or megakaryocytes (Figure 2, D) or both.
Almost 30 years ago, Harker and Finch [1] showed an inverse relation between platelet count (PLT) and megakaryocyte volume.
Dysmegakaryocytopoieisis with discrete megakaryocyte nuclei lacking lobation ("pawn ball" nuclei) and dwarf megakaryocytes may be observed (Slide 5b).
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
9) A decrease in C-MYB levels occurs in thrombopoietin-induced megakaryocyte maturation (Figure 3).
Furthermore, osteoblasts were shown to be important mediators of B cell and megakaryocyte differentiation (80), (81).
Previous research has suggested that stimulation of the TPO/thrombopoietin-receptor pathway, which is considered the master regulator of megakaryocyte production, may be an attractive strategy for increasing platelet count.
In addition to identifying a highly valuable new target for therapeutic development in GPS, this research confirms the central role of the GFI1B gene as a master regulator of megakaryocyte and platelet production - an insight that could be useful in research on a wide range of platelet disorders.